肝细胞癌的瘤内核型异质性与克隆演化
该研究基于111例人肝细胞癌样本,采用定量数字病理、全外显子组测序和RNA测序,将HCC分为二倍体(DP)和高倍体(HP)亚型,发现HP-HCC与增殖性分子亚类、不良预后及干性特征相关,空间转录组学证实高倍体肿瘤肝细胞通过二倍体细胞的全基因组加倍克隆演化而来。
要点
- 数字病理可基于核形态计量将HCC分为DP和HP亚型并定位高倍体核空间分布。
- HP-HCC关联增殖性分子亚类、不良预后和干性特征。
- 混合DP/HP-HCC中高倍体灶与HP-HCC转录组相似并显示基因组不稳定。
核心结论
- 核倍体分析对HCC具有预后价值,高倍体HCC由瘤内高倍体灶克隆演化而来。
研究设计与样本
- 对111例人HCC样本进行定量数字病理倍体评估、全外显子组测序和bulk RNA测序。
- 采用宏观切割FFPE肿瘤组织的3' mRNA测序和空间转录组学探究高倍体克隆的克隆演化。
主要发现
- 基于全切片成像的定量数字病理,依据核形态计量将HCC分为二倍体(DP)和高倍体(HP)亚型,并定位瘤内高倍体核的空间分布。
- 转录组分析显示HP-HCC与以不良预后和干性特征为特点的增殖性分子亚类相关。
- 空间重建识别出混合DP/HP-HCC,其中高倍体核在二倍体肿瘤背景中形成离散簇。
- 这些新生高倍体灶与HP-HCC共享转录组谱并显示基因组不稳定特征。
- DP/HP-HCC的空间转录组学提供直接证据表明高倍体肿瘤肝细胞通过二倍体细胞的全基因组加倍产生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC), the fourth leading cause of cancer-related death worldwide, still lacks robust stratification biomarkers to improve prognostication and prediction of treatment response. Polyploidization or hyperploidization, an early event observed in many solid tumours, may represent such a biomarker. Here, we developed a novel high-throughput, in situ quantitative digital pathology approach to assess nuclear ploidy in HCC and evaluate its prognostic relevance. METHODS: Quantitative digital pathology-based ploidy assessment, whole-exome sequencing (WES), and bulk RNA sequencing were performed on 111 human HCC samples. To investigate the clonal evolution of hyperploid clones within tumours, 3' mRNA sequencing of macrodissected FFPE tumour tissue and spatial transcriptomics were employed. RESULTS: Using whole-slide imaging-based quantitative digital pathology, we classified HCCs into diploid (DP) and hyperploid (HP) subtypes based on nuclear morphometry and mapped the spatial distribution of hyperploid nuclei within tumours. Transcriptomic analysis associated HP-HCCs with a proliferative molecular subclass characterized by poor prognosis and stemness features. Spatial reconstruction of nuclear ploidy further identified mixed DP/HP-HCCs, in which hyperploid nuclei formed discrete clusters within an otherwise diploid tumour background. Notably, these nascent hyperploid foci shared a transcriptomic profile with HP-HCCs and exhibited signatures of genomic instability. Importantly, spatial transcriptomics of DP/HP-HCCs provided direct evidence that hyperploid tumour hepatocytes arise through whole-genome doubling of diploid cells. CONCLUSIONS: These findings highlight the prognostic value of nuclear ploidy profiling in HCC and suggest that hyperploid HCCs evolve clonally from intratumoural hyperploid foci. Hyperploidization may therefore represent a key mechanism driving genomic instability in liver tumourigenesis. IMPACT AND IMPLICATIONS: Modification of ploidy play a substantial role in cancer genome evolution. In this study, we created a new digital pathology method to accurately measure the hepatocyte ploidy profile of HCC. This powerful tool reveals three distinct tumour types: diploid (DP), hyperploid (HP), and mixed diploid/hyperploid (DP/HP) HCCs. By clearly defining these groups, we gain crucial, new insights into the "branching" evolution of HCC tumours. This study should pave the way for novel diagnostic and therapeutic strategies.
引用
- Cordier P, Hirsch TZ, Caruso S, et al. Intratumour ploidy heterogeneity and clonal evolution in hepatocellular carcinoma. J Hepatol. 2025. PMID: 41297676. doi:10.1016/j.jhep.2025.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。